Glucocorticoid-induced osteoporosis: 2019 concise clinical review

Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan

(2019) K. Moriwaki et al.   OSTEOPOROSIS INTERNATIONAL

Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study

(2018) Zoe Paskins et al.   BMC Medicine

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

(2018) Kenneth G Saag et al.   Lancet Diabetes & Endocrinology

Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study

(2018) M. Amine Amiche et al.   Archives of Osteoporosis

Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone

(2017) Kristian F. Axelsson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Glucocorticoid use and its association with skeletal health among U.S. adults with diabetes

(2017) Sarah Stark Casagrande et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Imminent fracture risk

(2017) C. Roux et al.   OSTEOPOROSIS INTERNATIONAL

Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center

(2017) J. H. Koh et al.   OSTEOPOROSIS INTERNATIONAL

Oral glucocorticoid use and osteonecrosis in children and adults with chronic inflammatory diseases: a population-based cohort study

(2017) Daniel B Horton et al.   BMJ Open

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

(2017) Lenore Buckley et al.   Arthritis & Rheumatology

UK clinical guideline for the prevention and treatment of osteoporosis

(2017) J. Compston et al.   Archives of Osteoporosis

Factors associated with osteoporosis in patients with chronic obstructive pulmonary disease—a nationwide retrospective study

(2016) P.-C. Lu et al.   OSTEOPOROSIS INTERNATIONAL

Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis

(2016) A. Balasubramanian et al.   OSTEOPOROSIS INTERNATIONAL

Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide

(2016) Kenneth G. Saag et al.   Arthritis & Rheumatology

Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis

(2015) Leonardo Mellibovsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996–2012

(2015) J. M. Albaum et al.   OSTEOPOROSIS INTERNATIONAL

Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials

(2015) M. A. Amiche et al.   OSTEOPOROSIS INTERNATIONAL

2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis

(2014) Karine Briot et al.   JOINT BONE SPINE

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

(2014) Yasuo Suzuki et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

(2014) Aliya A Khan et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Abnormalities in Cortical Bone, Trabecular Plates, and Stiffness in Postmenopausal Women Treated With Glucocorticoids

(2014) Stephanie Sutter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial

(2013) Claus-C Glüer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

(2013) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom

(2013) I. E. M. Bultink et al.   OSTEOPOROSIS INTERNATIONAL

Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case–control study using HR-pQCT

(2012) X. L. Tang et al.   OSTEOPOROSIS INTERNATIONAL

Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort

(2012) Emily McKeown et al.   RHEUMATOLOGY

Prevalence of oral glucocorticoid usage in the United States: A general population perspective

(2012) Robert A. Overman et al.   ARTHRITIS CARE & RESEARCH

Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts

(2011) Maria Almeida et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Guidance for the adjustment of FRAX according to the dose of glucocorticoids

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial

(2010) C. C. Mok et al.   ANNALS OF THE RHEUMATIC DISEASES

Altered trabecular architecture induced by Corticosteroids: A Bone Histomorphometric Study

(2010) D. Chappard et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures

(2010) Lidwien Graat-Verboom et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice

(2009) Robert S. Weinstein et al.   AGING CELL

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Ibandronate Prevents Bone Loss and Reduces Vertebral Fracture Risk in Male Cardiac Transplant Patients: A Randomized Double-Blind, Placebo-Controlled Trial*

(2009) Astrid Fahrleitner-Pammer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis

(2009) J.-P. DEVOGELAER et al.   JOURNAL OF RHEUMATOLOGY

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

(2009) S. A. STOCH et al.   JOURNAL OF RHEUMATOLOGY

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis

(2009) T. Beukelman et al.   OSTEOPOROSIS INTERNATIONAL

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

(2009) B. L. Langdahl et al.   OSTEOPOROSIS INTERNATIONAL

BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: Potential therapeutic targets for glucocorticoid-induced osteoporosis

(2008) Kumi Hayashi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL